<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03935152</url>
  </required_header>
  <id_info>
    <org_study_id>286/2019</org_study_id>
    <nct_id>NCT03935152</nct_id>
  </id_info>
  <brief_title>Oral Dydrogesterone in the Management of Preterm Labor</brief_title>
  <official_title>Oral Dydrogesterone as Adjunctive Therapy in the Management of Preterm Labor: A Randomized, Double Blinded, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the addition of oral dydrogesterone to standard treatment in the
      treatment of preterm labor. Half of participants will receive oral dydrogesterone and
      standard treatment, while the other half will receive oral placebo and standard treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2019</start_date>
  <completion_date type="Anticipated">October 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>latency period</measure>
    <time_frame>13 weeks</time_frame>
    <description>time from preterm labor to delivery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>preterm delivery less than 34 weeks</measure>
    <time_frame>10 weeks</time_frame>
    <description>percentage of delivery less than 34 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>preterm delivery less than 37 weeks</measure>
    <time_frame>13 weeks</time_frame>
    <description>percentage of delivery less than 37 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal complications</measure>
    <time_frame>13 weeks</time_frame>
    <description>percentage of newborn with RDS, IVH, NEC, death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects</measure>
    <time_frame>13 weeks</time_frame>
    <description>percentage of side effects such as headache, nausea/vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>compliance</measure>
    <time_frame>13 weeks</time_frame>
    <description>percentage of complete drug use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>satisfaction</measure>
    <time_frame>13 weeks</time_frame>
    <description>percentage of good satisfaction</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Preterm Labor</condition>
  <arm_group>
    <arm_group_label>Dydrogesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dydrogesterone 10 mg by mouth every 8 hours until delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo by mouth every 8 hours until delivery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dydrogesterone</intervention_name>
    <description>dydrogesterone capsule</description>
    <arm_group_label>Dydrogesterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  singleton pregnancy with gestational age 24-33 weeks 6 days

          -  preterm labor

          -  received treatment with tocolysis and corticosteroids

        Exclusion Criteria:

          -  conditions that need immediate delivery such as fetal distress, chorioamnionitis

          -  have medical complications such as heart disease, seizure

          -  fetal anomalies

          -  cervical dilatation more than 5 cm

          -  allergy to dydrogesterone
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vorapong Phupong, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Chulalongkorn University, Faculty of Medicine, Department of Obstetrics and Gynecology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vorapong Phupong, M.D.</last_name>
    <phone>026492115</phone>
    <email>vorapong.p@chula.ac.th</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Suparudeewan Thongchan, M.D.</last_name>
    <phone>026492115</phone>
    <email>dewiifleur@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine, Chulalongkorn University</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vorapong Phupong, MD</last_name>
      <phone>26492115</phone>
      <email>vorapong.p@chula.ac.th</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Obstetrics. Practice Bulletin No. 171: Management of Preterm Labor. Obstet Gynecol. 2016 Oct;128(4):e155-64. doi: 10.1097/AOG.0000000000001711. Review.</citation>
    <PMID>27661654</PMID>
  </reference>
  <reference>
    <citation>Blencowe H, Cousens S, Chou D, Oestergaard M, Say L, Moller AB, Kinney M, Lawn J; Born Too Soon Preterm Birth Action Group. Born too soon: the global epidemiology of 15 million preterm births. Reprod Health. 2013;10 Suppl 1:S2. doi: 10.1186/1742-4755-10-S1-S2. Epub 2013 Nov 15. Review.</citation>
    <PMID>24625129</PMID>
  </reference>
  <reference>
    <citation>Norwitz ER, Caughey AB. Progesterone supplementation and the prevention of preterm birth. Rev Obstet Gynecol. 2011 Summer;4(2):60-72.</citation>
    <PMID>22102929</PMID>
  </reference>
  <reference>
    <citation>Yasuda K, Sumi GI, Murata H, Kida N, Kido T, Okada H. The steroid hormone dydrogesterone inhibits myometrial contraction independently of the progesterone/progesterone receptor pathway. Life Sci. 2018 Aug 15;207:508-515. doi: 10.1016/j.lfs.2018.07.004. Epub 2018 Jul 4.</citation>
    <PMID>29981319</PMID>
  </reference>
  <reference>
    <citation>Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH. Classification and pharmacology of progestins. Maturitas. 2008 Sep-Oct;61(1-2):171-80.</citation>
    <PMID>19434889</PMID>
  </reference>
  <results_reference>
    <citation>Borna S, Sahabi N. Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Aust N Z J Obstet Gynaecol. 2008 Feb;48(1):58-63. doi: 10.1111/j.1479-828X.2007.00803.x.</citation>
    <PMID>18275573</PMID>
  </results_reference>
  <results_reference>
    <citation>Arikan I, Barut A, Harma M, Harma IM. Effect of progesterone as a tocolytic and in maintenance therapy during preterm labor. Gynecol Obstet Invest. 2011;72(4):269-73. doi: 10.1159/000328719. Epub 2011 Nov 12.</citation>
    <PMID>22086108</PMID>
  </results_reference>
  <results_reference>
    <citation>Choudhary M, Suneja A, Vaid NB, Guleria K, Faridi MM. Maintenance tocolysis with oral micronized progesterone for prevention of preterm birth after arrested preterm labor. Int J Gynaecol Obstet. 2014 Jul;126(1):60-3. doi: 10.1016/j.ijgo.2014.01.019. Epub 2014 Apr 3.</citation>
    <PMID>24807871</PMID>
  </results_reference>
  <results_reference>
    <citation>Areeruk W, Phupong V. A randomized, double blinded, placebo controlled trial of oral dydrogesterone supplementation in the management of preterm labor. Sci Rep. 2016 Feb 9;6:20638. doi: 10.1038/srep20638.</citation>
    <PMID>26856618</PMID>
  </results_reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>April 30, 2019</study_first_submitted>
  <study_first_submitted_qc>April 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2019</study_first_posted>
  <last_update_submitted>July 23, 2019</last_update_submitted>
  <last_update_submitted_qc>July 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Vorapong Phupong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Obstetric Labor, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dydrogesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

